What are the price targets for organigram's shares?
9 equities research analysts have issued 1 year price targets for OrganiGram's shares. Their forecasts range from C$2.25 to C$5.00. On average, they anticipate OrganiGram's share price to reach C$3.48 in the next twelve months. This suggests a possible upside of 80.3% from the stock's current price.
Is organigram efficiently growing its dividend?
OrganiGram does not have a long track record of dividend growth. In the past three months, OrganiGram insiders have not sold or bought any company stock. Only 11.78% of the stock of OrganiGram is held by institutions. Earnings for OrganiGram are expected to grow in the coming year, from ($0.09) to ($0.06) per share.
How much of organigram stock is owned by institutions?
Only 11.78% of the stock of OrganiGram is held by institutions. Earnings for OrganiGram are expected to grow in the coming year, from ($0.09) to ($0.06) per share.
Did organigram insiders sell or buy the stock?
In the past three months, OrganiGram insiders have not sold or bought any company stock. Only 11.78% of the stock of OrganiGram is held by institutions. Earnings for OrganiGram are expected to grow in the coming year, from ($0.09) to ($0.06) per share.
Is OrganiGram a Buy Sell or Hold?
OrganiGram has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Is OrganiGram expected to go up?
The 10 analysts offering 12-month price forecasts for OrganiGram Holdings Inc have a median target of 2.02, with a high estimate of 2.90 and a low estimate of 1.59. The median estimate represents a +119.95% increase from the last price of 0.92.
Does OrganiGram stock pay dividends?
ORGANIGRAM HOLDINGS (NASDAQ: OGI) does not pay a dividend.
How many outstanding shares does OGI have?
Share StatisticsAvg Vol (3 month) 34.53MShares Outstanding 5313.69MImplied Shares Outstanding 6N/AFloat 8252.41M% Held by Insiders 118.66%7 more rows
Should I sell my organigram stock?
Organigram Holdings(OGI-X) Rating A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Is OGI a good buy now?
The financial health and growth prospects of OGI, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
When did OGI go public?
January 5, 2012OGI stock went public on January 5, 2012 and ended the day at $0.29. The stock has since gained 1,000%. So, a $500 investment in OGI just after its IPO is currently worth $5,000.
Should I buy or sell OrganiGram stock right now?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 3 hold ratings a...
What is OrganiGram's stock price forecast for 2022?
7 equities research analysts have issued twelve-month target prices for OrganiGram's shares. Their forecasts range from $2.25 to $5.30. On average,...
How has OrganiGram's stock performed in 2022?
OrganiGram's stock was trading at $1.75 at the start of the year. Since then, OGI stock has decreased by 40.0% and is now trading at $1.05. View t...
When is OrganiGram's next earnings date?
OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022. View our earnings forecast for OrganiGram .
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc. (NASDAQ:OGI) announced its quarterly earnings results on Tuesday, April, 12th. The company reported ($0.02) earnings per s...
Who are OrganiGram's key executives?
OrganiGram's management team includes the following people: Mr. Derrick W. West CPA , CPA, (CA), Chief Financial Officer (Age 55, Pay $241.72k)...
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include BELLUS Health (BLUSF) , Madrigal Pharmaceuticals (MDGL) , Lyell Immunopharma (LYEL) , Cry...
What other stocks do shareholders of OrganiGram own?
Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB) , (CGC) ,...
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
Is OrganiGram stock a Buy, Sell or Hold?
OrganiGram stock has received a consensus rating of sell. The average rating score is and is based on 0 buy ratings, 0 hold ratings, and 1 sell rat...
What was the 52-week low for OrganiGram stock?
The low in the last 52 weeks of OrganiGram stock was 1.07. According to the current price, OrganiGram is 103.74% away from the 52-week low.
What was the 52-week high for OrganiGram stock?
The high in the last 52 weeks of OrganiGram stock was 3.52. According to the current price, OrganiGram is 31.58% away from the 52-week high.
What are analysts forecasts for OrganiGram stock?
The 1 analysts offering price forecasts for OrganiGram have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The m...
About OrganiGram
Headlines
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
CGC: Canopy Growth vs. OrganiGram: Which Cannabis Stock Is a Better Buy? - StockNews.com
Organigram Reports Highest Quarterly Net Revenue Ever In Q1, Remains Among Top Canadian Cannabis LPs
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock.
Benzinga Interview: Organigram CEO Beena Goldenberg Discusses Company Performance And Canadian Cannabis Market
Cannabis company Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced its results for the first quarter ended November 30, 2021.
Should I hold Organigram stock?
OrganiGram Holdings Inc (NASDAQ: OGI) (TSE: OGI) CEO Beena Goldenberg recently spoke with Benzinga to discuss the company's ongoing growth and Q2 success.
Is Organigram a hold?
The consensus among Wall Street analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
OGI Overview
Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrganiGram wasn't one of them.
Zen Score
OrganiGram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis... read more
Due Diligence Checks
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OGI scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Profit margin
OGI's profit margin has increased... subscribe to Premium to read more.
Assets to liabilities
OGI's cash and short-term investments... subscribe to Premium to read more.
Cash flow
OGI's short-term assets ($193.17M) exceed... subscribe to Premium to read more.
What is Organigram Holdings?
OGI's cash and short-term investments... subscribe to Premium to read more.
Who makes cannabis products?
OrganiGram Holdings Inc is a drug manufacturers-specialty & generic business based in the US. OrganiGram shares (OGI) are listed on the NASDAQ and all prices are listed in US Dollars. OrganiGram employs 619 staff and has a trailing 12-month revenue of around 0.00.
Organigram CEO: BAT has the management, R&D, consumer insight and regulatory expertise to help Organigram pursue its goals
Organigram Holdings Inc. , through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co. , ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc.
Referenced Symbols
Organigram Holdings Inc.’s U.S.-listed shares were on track for a 51% gain on the week Friday, buoyed by the news that the Canadian cannabis company has received a C$221 million ($176.6 million) investment from a unit of British American Tobacco PLC.